Investment Analysts’ Weekly Ratings Changes for AtriCure (ATRC)

AtriCure (NASDAQ: ATRC) recently received a number of ratings updates from brokerages and research firms:

• 2/21/2026 – AtriCure was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 2/18/2026 – AtriCure had its price target lowered by UBS Group AG from $60.00 to $55.00. They now have a “buy” rating on the stock.
• 2/18/2026 – AtriCure had its price target lowered by Canaccord Genuity Group Inc. from $64.00 to $53.00. They now have a “buy” rating on the stock.
• 2/18/2026 – AtriCure was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 2/18/2026 – AtriCure was given a new $44.00 price target by Oppenheimer Holdings, Inc..
• 2/18/2026 – AtriCure had its “outperform” rating reaffirmed by Citigroup Inc..
• 2/18/2026 – AtriCure was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/18/2026 – AtriCure had its price target lowered by Citizens Jmp from $60.00 to $52.00. They now have a “market outperform” rating on the stock.
• 2/18/2026 – AtriCure had its “buy” rating reaffirmed by BTIG Research. They now have a $54.00 price target on the stock.
• 2/12/2026 – AtriCure had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $45.00 price target on the stock.
• 2/11/2026 – AtriCure was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $36.00 price target on the stock.
• 1/21/2026 – AtriCure had its “sell (d-)” rating reaffirmed by Weiss Ratings.

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.